论文部分内容阅读
目的研讨儿童哮喘患者接受不同剂量布地奈德与孟鲁司特钠治疗对肺功能、免疫功能的改善作用。方法从我院2015年3月-2017年1月选取86例儿童哮喘患者做试验分析,并按随机非盲法归组(43例/组),两组均在孟鲁司特钠给药下接受布地奈德雾化吸入,其中Ⅰ组布地奈德取0.5mg,1次/12h,Ⅱ组用量取1.0mg,1次/12h,观察两组药物方案的临床应用情况。结果两组治疗后接受肺功能(FEV1、FEV1/FVC)及免疫功能(CD4+、CD8+)指标检测,测定值相比治疗前均显著改善,比较差异显著(P<0.05);但组间比较,差异不显著(P>0.05)。两组试验期间均有产生口干或心悸等副反应,但发生率相比,差异不显著(P>0.05)。结论对儿童哮喘患者使用高、低剂量(1.0mg与0.5mg)布地奈德雾化吸入配合孟鲁司特钠治疗,对肺功能及免疫功能均有良好的改善作用,且安全可靠,可作为推荐剂量使用。
Objective To investigate the effect of budesonide and montelukast sodium on the improvement of pulmonary function and immune function in children with asthma. Methods Eighty-six children with asthma were selected from March 2015 to January 2017 in our hospital for trial analysis. Randomized non-blinded patients (43 cases / group) were treated with montelukast sodium Received budesonide inhalation, in which budesonide group Ⅰ take 0.5mg, 1 / 12h, the amount of group Ⅱ to take 1.0mg, 1 / 12h, observed the clinical application of two groups of drug regimens. Results After treatment, the lung function (FEV1, FEV1 / FVC) and immune function (CD4 +, CD8 +) were detected in both groups. The measured values were significantly improved compared with those before treatment (P <0.05) The difference was not significant (P> 0.05). No side effects such as dry mouth or palpitations occurred during the two groups, but the difference was not significant (P> 0.05). Conclusions The use of high and low dose budesonide inhalation combined with montelukast sodium in children asthma patients has good effect on lung function and immune function and is safe and reliable Recommended dosage.